[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amnestic-mild-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amnestic-mild-cognitive-impairment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,81,108,129,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100515092","sleep-interventions-and-neurocognitive-outcomes-100515092",false,"NCT05987007","Sleep Interventions and Neurocognitive Outcomes","Sleep Interventions and Neurocognitive Outcomes in Amnestic Mild Cognitive Impairment","Inclusion Criteria:\n\n1. English speaking participants, ages 60-85 years\n2. Telephone MMSE (T-MMSE) score of 22 or greater at screening assessment; T-MMSE \\\u003C18 during post-treatment visit or 6-month follow-up will be discontinued from participation of the study.\n3. Individuals with aMCI, as determined by the Wechsler Memory Scale-Revised Logical Memory Delayed Recall (LM) and Quick Dementia Rating Scale (QDRS)\n4. Presence of subject memory complains not exclusionary. Presence of subjective memory complaints without objective signs of impairment (T-MMSE, QDRS, LM) would not be considered as the presence of late MCI or dementia, therefore are not exclusionary.\n5. Participants with regular and consistent use of sleep medications (sedatives\u002Fhypnotic use of \\>3 times per week) will be excluded. Participants who take sleep medications 3 or less times per week will be asked to discontinue medications prior to the study baseline visit. All discontinuation\u002Ftapering procedures will require PI's direct consultation with participants' prescribing or primary care physicians, which will be documented to ensure participants' safety.\n6. Presence of sleep disturbance, as determined by score of 8 or greater on the Insomnia Severity Index administered at baseline (without sleep medications).\n7. Participants must have capacity to provide informed consent.\n8. Have access to stable internet connection.\n9. A family member or other individual who is in contact with the subject and consents to serve as informant during the study; this can be a telephone informant in the case of subjects who do not have a live-in informant\n\nExclusion Criteria:\n\n1. Diagnosis of stroke or excessive risk of CVD\n2. Neurologic disease including movement disorders, MS, epilepsy, and TBI (with greater than 15 min loc)\n3. Untreated diabetes\n4. Active treatment of cancer\n5. Telephone MMSE score below 22 (Newkirk et al., 2004) and Logical Memory above 11 for subjects with 16 or more years of education, 9 for subjects with 8-15 years of education, and 6 for subjects with 0-7 years of education\n6. Presence of sleep disorders other than insomnia (moderate-severe sleep apnea, REM-behavior disorder, restless legs syndrome, circadian rhythm disorder). Mild sleep apnea will not be exclusionary.\n7. Current DSM-5 Axis I psychiatric diagnosis of schizophrenia, schizoaffective disorder, substance\u002Falcohol use disorder, or bipolar disorder\n8. Use of antidepressants with known large anticholinergic properties will be excluded. These include: amitriptyline, amoxapine, clomipramine, desipramine, doxepine, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine. Other medications are allowed during the study and are not exclusionary.\n9. Participants taking medications with benzodiazepines properties will be excluded. These include: diazepam, quazepam, estazolam, alprazolam, clorazepate, clorazepate, oxazepam, alprazolam, chlordiazepoxide, lorazepam, flurazepam, triazolam, temazepam, and midazolam.\n10. Participants with moderate to severe depression (Geriatric Depression Scale\\>8) will be excluded from the study and will be encouraged to seek treatment for their symptoms. Participants with moderate depression (GDS 5-8) will be encouraged to return for screening after receiving treatment and seeing improvement in their symptoms.\n11. Participants who are unable to provide an informant.","ALL","60 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This protocol focuses on the effect of sleep interventions on improving sleep and building cognitive\u002Fbrain resilience in older adults with amnestic mild cognitive impairment and sleep disturbance. Two sleep interventions, cognitive behavioral therapy for insomnia (CBTI) and acoustic slow-wave activity enhancement (SWAE), will be utilized in a pilot randomized clinical trial in which participants are randomized to different treatment groups (CBTI or SWAE). Participants will be assessed over a 6-month period in order to examine the impact of sleep treatments on neuropsychological outcomes and cognitively mediated everyday functioning.",[27,28],"Sleep Disturbance","Amnestic Mild Cognitive Impairment",[30,31,32,28,33],"Alzheimer's Disease","Slow-Wave Activity","Older Adults","Cognitive Behavioral Therapy for Insomnia","NOT_YET_RECRUITING","2026-06-08",{"date":37,"type":38},"2026-06-09","ACTUAL",{"date":40,"type":21},"2026-07-01",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"New York State Psychiatric Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100473568","phase-2-pathways-relating-amnestic-mci-to-a-mild-traumatic-brain-injury-history-100473568","NCT05446584","Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History","PATH","Inclusion Criteria:\n\n1. Active diagnosis of amnestic mild cognitive impairment\n2. Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample\n3. Female and male subjects\n4. All races\u002Fethnicities\n5. Age 55 years and older\n6. Fluent in English\n\nExclusion Criteria:\n\n1. Mild traumatic brain injury within past year\n2. Lifetime history of moderate or severe brain injury\n3. Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor)\n4. Lifetime major cardiovascular conditions (e.g., heart attack, heart failure)\n5. Current substance use disorder\n6. Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder)\n7. Current vision or hearing impairment that interferes with testing\n8. Any electronic and or metallic implants in the skull or brain\n9. Current medication use known to alter HD-tDCS reactivity","55 Years",{"count":56,"type":21},75,[58],"PHASE2","This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.",[61,62,28,63,64],"Mild Cognitive Impairment","Amnestic Mild Cognitive Disorder","Mild Traumatic Brain Injury","Concussion, Brain",[66,67,68,69,70],"MCI","TBI","memory","biomarker","Alzheimer","RECRUITING","2026-05-05",{"date":74,"type":38},"2026-05-06",{"date":76,"type":38},"2023-04-20",{"date":78,"type":21},"2027-05-31",{"name":80,"class":45},"University of Texas Southwestern Medical Center",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100380974","characterizing-variability-in-hearing-aid-outcomes-in-among-older-adults-with-alzheimers-dementia-100380974","NCT04240561","Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia","Inclusion Criteria:\n\n1. Speak English as their primary language\n2. Normal or corrected to normal vision (20\u002F40 binocular vision or unaided using a Snellen chart)\n3. Sensorineural hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 500 and 3000 Hz and a 4 frequency (.5, 1, 2, 3 kHz) pure-tone average of greater than or equal to 30 dB in each ear\n4. Clinical Dementia Rating (CDR) of 0.5 or 1 (indicating slight or mild cognitive impairment in the areas of memory, orientation, judgment\u002Fproblem solving, community affairs, behavior at home\u002Fhobbies, and personal care)\n5. Diagnosis of dementia Alzheimer's type or amnestic mild cognitive impairment (minimum MoCA score of 18).\n6. Living at home\n7. Minimum Grade 10 education\n8. Able to provide own consent as evaluated by the Consent Assessment.\n\nExclusion Criteria:\n\n1. Clinically significant unstable or progressive medical conditions, or conditions which, in the opinion of the investigator(s) places the participant at unacceptable risk if he or she were to participate in the study\n2. History of unresolved communication difficulties following another neurological problem (e.g. stroke or brain tumor), neurodevelopmental disorder (e.g. Down's syndrome), or head\u002Fneck cancer\n3. Positive history of major psychiatric disorder (e.g. schizophrenia, significant untreated depression)\n4. Co-enrolled in other intervention studies targeting hearing, language, or communication strategies\n5. Conductive hearing loss pathology, congenital hearing loss, or fluctuating hearing loss\n6. Current active hearing aid wearer (defined as wearing hearing aid(s) at least 4 hours a day for most days within the past year)","50 Years","90 Years",{"count":90,"type":21},20,[24],"This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild cognitive impairment. The investigators hypothesize that adults with Alzheimer's dementia represent an extreme case of restricted cognitive ability, such that very low working memory capacity and overall reduced cognitive capacity will limit benefit from advanced signal processing. Thus, the investigators hypothesize that adults with Alzheimer's dementia will receive greater benefit from acoustically simple, high-fidelity hearing aid processing that minimally alters the acoustic signal.",[94,95,28],"Hearing Loss, Sensorineural","Dementia of Alzheimer Type",[97],"mild cognitive impairment","2026-04-28",{"date":100,"type":38},"2026-04-30",{"date":102,"type":38},"2021-07-01",{"date":104,"type":21},"2027-08-31",{"name":106,"class":45},"Northwestern University",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100508680","training-response-artificial-intelligence-network-train-100508680","NCT05903573","Training Response Artificial Intelligence Network (TRAIN)","Using Artificial Intelligence to Predict Cognitive Training Response in Amnestic Mild Cognitive Impairment","Inclusion Criteria:\n\n* Evidence of changed cognition reported by a close informant as obtained by an interview with a licensed clinical psychologist (PI, Gullett)\n* Cognitive performance on one or more standardized neuropsychological measures of verbal or non-verbal memory \\> 1.0 standard deviation or more below the normative mean for age and education\n* No evidence of reported dependence in instrumental functional abilities (IADLs) despite reported cognitive difficulties\n* No evidence of dementia based on cognitive screening (Montreal Cognitive Assessment Score within normal limits for age, education, and sex using the NACC Uniform Data Set (UDS) norms.\n* Global clinical dementia rating scale (CDR) score must be equal to 0.5\n* Willingness to be randomized into either the educational training (control) or intervention (cognitive training) group\n* Able and willing to devote 12 weeks to the intervention with additional time for pre- and post-testing\n* Able and willing to perform cognitive and emotional measures both on paper and on a tablet computer\n* In line with the recommendations of the SCD task force, an informant must be available. This is to a) obtain information about the participant's complaints and cognitive difficulties on interview, and b) to ascertain validity of self-reported IADL function in regard to instrumental functional activities.\n\nExclusion Criteria:\n\n* Sensory loss (vision, hearing) or motor deficits that would preclude participation in the experimental tasks or neuropsychological assessment\n* English as a second language\n* Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal\n* Previous major strokes or other known significant brain abnormalities or diseases affecting the brain and\u002For cognition (e.g., Parkinson disease, multiple sclerosis, seizure disorder, brain surgery, moderate TBI, REM Behavior Sleep Disorder, untreated sleep apnea, etc.)\n* Unstable and uncontrolled medical conditions (metastatic cancer, HIV, moderate-severe kidney disease, uncontrolled diabetes, uncontrolled hypertension, severe cardiac disease, etc.). No current cancer diagnosis\n* Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. The investigators are not excluding individuals who are taking antidepressant or anti-anxiety medications, however, use of these medications will be recorded and data analyzed in post-hoc analyses\n* Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)\n* Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention.\n* Previous participation in a cognitive training study within the last 6 months or current involvement in another study involving cognitive, physical or other intervention at the time of participation.","100 Years",{"count":56,"type":21},[24],"This study will train a machine learning tool to predict response to a cognitive training intervention using baseline brain MRI sequences from older adults with amnestic mild cognitive impairment.",[28],"2025-12-03",{"date":122,"type":38},"2025-12-04",{"date":124,"type":38},"2023-10-09",{"date":126,"type":21},"2028-04-30",{"name":128,"class":45},"University of Florida",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100550245","modified-ketogenic-diet-in-amnestic-mild-cognitive-impairments-100550245","NCT06444568","Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments","Efficacy of Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments","Inclusion Criteria:\n\n* Having been diagnosed with \"amnestic mild cognitive impairment\u002Fdisorder (aMCI)\" by the clinician after the evaluation of cognitive functions according to the neuropsychological evaluation method (0.5 according to the Clinical Dementia Rating Scale (CDR).)\n* Having at least 6 years of education.\n\nExclusion Criteria:\n\n* Under the age of 65 or over the age of 80.\n* Diagnosis of neurological (other than MCI) or psychological diseases.\n* GDS-15 score \\> 5 (baseline)\n* Kidney\u002Fpancreas\u002Fliver diseases or dysfunctions, Type 1 diabetes (and Type II diabetic patients receiving insulin replacement therapy), cancer, metabolic diseases (fatty acid oxidation defect, etc.), thyroid dysfunction, pulmonary or autoimmune diseases, head trauma, history of any cardiovascular event (i.e., stroke, myocardial infarction) in the last year.\n* Hypercholesterolemia (fasting T-C \\>300 mg\u002FdL or LDL-C \\>200 mg\u002FdL), non-reference B12 or folate levels according to biochemical tests performed in the last year.\n* Nutritional risks (chewing\u002Fswallowing difficulties, history of involuntary weight loss in the last 6 months, body mass index \\\u003C 22 kg\u002Fm2).\n* Use of internal device\u002Fimplant (pacemaker or hearing aid, etc.).\n* Medication use (individuals using anticholinergic, antidementia, and opioid class drugs will be excluded; individuals using antidepressant class drugs will be included in the study on the condition that it has been continued for at least 3 months and there is no change in drug type and dose during the study protocol.)","65 Years","80 Years",{"count":139,"type":21},36,[24],"This clinical study aims to examine the effectiveness of a 12-week modified ketogenic diet (MKD) intervention, especially on cognitive functions, in individuals diagnosed with amnestic-mild cognitive impairment (aMCI) and to compare the effects of control groups (passive or active).\n\nAccordingly, a sample of 36 older adults aged 65-80 years diagnosed with aMCI will be randomized into 3 different groups: passive control (without any intervention), active control (MIND: Mediterranean-DASH Intervention for Neurodegenerative Delay diet) or intervention (MKD). They will be monitored according to targeted criteria throughout the 12-week study protocol.\n\nThe main questions this study aims to answer are:\n\n* Does a 12-week MKD intervention improve cognitive functions in aMCI?\n* Does the effectiveness of the 12-week MKD intervention in aMCI (i.e., in terms of cognitive function, physical and functional measures, or metabolic\u002Finflammatory biomarkers) differ from control groups?\n\nExpected from participants during the study protocol:\n\n* Participants assigned to the passive control arm are expected to come to the research center at the beginning (week 0) and end (week 12) of the protocol and participate in evaluations.\n* Participants assigned to the active control (MIND diet) or intervention (MKD) arm are expected to adhere to assigned dietary therapy, keep a weekly food diary, and have weekly phone calls or online meetings with the dietitian to follow up on the diet. These participants assigned to the diet groups are expected to come to the research center at weeks 0, 4, 8, and 12 to participate in the evaluations.",[62,28],"2024-11-20",{"date":145,"type":38},"2024-11-25",{"date":147,"type":38},"2024-05-20",{"date":149,"type":21},"2025-03-01",{"name":151,"class":45},"Saglik Bilimleri Universitesi",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":16,"minAge":160,"maxAge":137,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100519980","mri-guided-closed-loop-tms-eeg-100519980","NCT06050603","MRI Guided Closed-loop TMS-EEG","Spatiotemporally Precise Neuromodulation by Transcranial Magnetic Stimulation Guided by Multimodal Neuroimaging","Inclusion Criteria for Healthy participants:\n\n* Ages between 18 and 65 years;\n* Healthy with no history of neurological impairment;\n* Normal or correct-to-normal vision.\n\nInclusion Criteria for aMCI patients:\n\n* Age 50-80 years;\n* MCI clinical criteria: (a) self- or informant-reported cognitive complaint; (b) preserved independence in functional abilities; and (c) absence of dementia;\n* Objective cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) 24-27 (inclusive); (b) Montreal Cognitive Assessment (MoCA) 18-26 (inclusive); or (c) Clinical Dementia Rating Scale score of 0.5;\n* Normal or correct-to-normal vision.\n\nExclusion Criteria for all participants:\n\n* Women who are pregnant or breastfeeding;\n* History of seizure (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain tumor, brain surgery, head injury, known structural brain lesion;\n* Have metal in the eye or skull area, brain stimulator, surgical metal, clips in the brain, cochlear implants, mental fragments in the eye, as these make TMS unsafe;\n* Have non-MRI compatible metal in the body, for example metallic (forromagnetic) implants (e.g., cardiac pacemaker, aneurysm clip);\n* Subjects who are uncomfortable in small closed spaces (have claustrophobia), unable to lie comfortably supine for up to 1 hour, and would feel uncomfortable in the MRI machine;\n* Participation in any other study involving non-invasive brain stimulation less than two weeks ago;\n* Abnormal findings on neurological examination that we will perform.",true,"18 Years",{"count":162,"type":21},160,[24],"The goal of this interventional study is to develop an individualized approach using transcranial magnetic stimulation (TMS) in a high-precision manner. This approach will use TMS to modulate brain activity at multiple locations simultaneously. Functional magnetic resonance imaging (fMRI) and electroencephalograph (EEG) will record the responses and guide the stimulation. Specifically, the placement and orientation of TMS coils will be tailored to stimulate the targeted functional brain areas informed by fMRI. To maximize the interventional effect, stimulation pulses will be delivered based on EEG oscillations.",[166,28],"Normal Physiology",[168,169],"Transcranial Magnetic Stimulation","Memory Impairments","2024-08-11",{"date":172,"type":38},"2024-08-13",{"date":174,"type":38},"2023-09-07",{"date":176,"type":21},"2027-07-31",{"name":178,"class":45},"Sunnybrook Health Sciences Centre"]